

In the Claims:

1. (Currently amended): A ~~vector~~ virus-ligand complex for delivery of a virus to a target cell within a host animal, comprising a cell-targeting ligand non-covalently bound directly to said virus, wherein upon introduction of said virus-ligand complex into a host animal, said ligand binds directly to a receptor on said target cell.

2. (Currently amended): The ~~vector~~ virus-ligand complex of claim 1 wherein said virus and said ligand are not naturally associated with each other.

3. (Currently amended): The ~~vector~~ virus-ligand complex of claim 1, wherein said virus ~~is comprised of~~ comprises a therapeutic nucleic acid.

4. ((Currently amended): The ~~vector~~ virus-ligand complex of claim 1, wherein said virus ~~is comprised of~~ comprises a nucleic acid that encodes a therapeutic peptide or protein.

5. (Currently amended): The ~~vector~~ virus-ligand complex of claim 1, wherein said virus ~~is comprised of~~ comprises a nucleic acid that encodes wild-type p53.

6. (Currently amended): The ~~vector~~ virus-ligand complex of claim 1, wherein said virus is a retrovirus or an adenovirus.

7. (Currently amended): The ~~vector~~ virus-ligand complex of claim 1, wherein said virus is selected from the group consisting of adeno-associated virus, herpes simplex virus, cytomegalovirus, vaccinia virus, fowlpox virus, canarypox virus and Sindbis virus.

8. (Currently amended): The ~~vector~~ virus-ligand complex of claim 1, wherein said virus is a chimeric virus, a hybrid virus, or a recombinant virus.

9. (Currently amended): The ~~vector~~ virus-ligand complex of claim 1, wherein said cell-targeting ligand is selected from the group consisting of proteins, peptides, hormones, antibodies and antibody fragments.

10. (Currently amended): The ~~vector~~ virus-ligand complex of claim 1, wherein said cell-targeting ligand is a native protein or a recombinant protein.

11. (Currently amended): The ~~vector~~ virus-ligand complex of claim 1, wherein said cell-targeting ligand is selected from the group consisting of insulin, toxins, epidermal growth factor (EGF) ~~EGF~~, vascular endothelial growth factor (VEGF) ~~VEGF~~, fibroblast growth factor (FGF) ~~FGF~~, insulin-like growth factor (IGF) ~~IGF~~, heregulin, a viral protein, a bacterial protein, estrogen and progesterone.

12. (Currently amended): The ~~vector~~ virus-ligand complex of claim 1, wherein said cell-targeting ligand is transferrin.

13. (Currently amended): The ~~vector~~ virus-ligand complex of claim 1, wherein said cell-targeting ligand and said virus are present at a ratio in the range of 100 to 1,000,000 ligand molecules per virion.

14. (Currently amended): The ~~vector~~ virus-ligand complex of claim 1, wherein said cell-targeting ligand and said virus are present at a ratio in the range of 6,700 to 400,000 ligand molecules per virion.

15. (Currently amended): The ~~vector~~ virus-ligand complex of claim 1, wherein said cell-targeting ligand and said virus are present at a ratio in the range of 1 µg to 10 mg of said ligand per 10¹⁰ virions.

16. (Currently amended): The ~~vector~~ virus-ligand complex of claim 1, wherein said cell-targeting ligand and said virus are present at a ratio in the range of 10 µg to 600 µg of said ligand per 10¹⁰ virions.

17. (Currently amended): A method for preparing a ~~vector~~ virus-ligand complex for the systemic delivery of a virus to a target cell, said ~~vector~~ virus-ligand complex comprising a cell-targeting ligand non-covalently bound directly to said virus, comprising mixing said cell-targeting ligand with said virus in ~~an~~ a cell-free aqueous medium, whereby said ligand non-covalently binds directly to said virus.

18. (Currently amended): The method of claim 17, wherein said cell-free aqueous solution includes one or more of a buffering agent, an osmolarity adjusting agent, or an antibiotic.

19-31. (Cancelled).

32. (Currently amended): The ~~vector~~ virus-ligand complex of claim 1, wherein said virus is an adenovirus comprising a therapeutic nucleic acid and said ligand is transferrin or EGF.

33. (Withdrawn-Currently amended): The ~~vector~~ virus-ligand complex of claim 1, wherein said virus is an adenovirus and said ligand is an antibody fragment.

34. (Currently amended): The ~~vector~~ virus-ligand complex of claim 32, wherein said adenovirus comprises a nucleic acid that encodes wild-type p53.

35. (Withdrawn-Currently amended): The ~~vector~~ virus-ligand complex of claim 33, wherein said adenovirus comprises a nucleic acid that encodes wild-type p53.

36. (Currently amended): The ~~vector~~ virus-ligand complex of claim 1, wherein said virus is a retrovirus or herpes simplex virus comprising a therapeutic nucleic acid and said ligand is transferrin.

37-44. (Cancelled).

45. (Currently amended): A ~~vector~~ virus-ligand complex prepared by the method of claim 17.

46-61. (Cancelled).

62. (New): A virus-ligand complex for delivery of a virus to a target cell within a host animal, consisting of a cell-targeting ligand non-covalently bound directly to said virus, wherein upon introduction of said virus-ligand complex into a host animal, said ligand binds directly to a receptor on said target cell.

63. (New): The virus-ligand complex of claim 62, wherein said virus comprises a nucleic acid or gene.

64. (New): A method for preparing a virus-ligand complex for the systemic delivery of a virus to a target cell, said virus-ligand complex consisting of a cell-targeting ligand non-covalently bound directly to said virus, comprising mixing said cell-targeting ligand with said virus in a cell-free aqueous medium, whereby said ligand non-covalently binds directly to said virus.

65 (New): The method of claim 64, wherein said virus comprises a nucleic acid or gene.